Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion

United Therapeutics (UTHR) News Today

United Therapeutics logo
$587.50 +2.71 (+0.46%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$592.41 +4.91 (+0.84%)
As of 10/23/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Why Is United Therapeutics Up Today?

United Therapeutics Corporation (NASDAQ: UTHR) has recently moved higher and is trading near its 52-week high. Investor sentiment is being supported by a large share-repurchase authorization and generally favorable analyst targets, although concerns about Tyvaso competition and insider selling are potential offsets.

  • Positive Sentiment: $2 billion buyback authorization: United Therapeutics’ board approved an additional $2 billion share-repurchase program, potentially covering up to 8.3% of outstanding shares. The authorization could reduce the share count, support future earnings per share and signal that management considers the stock undervalued. United Therapeutics Authorizes Additional $2 Billion Share Buyback Program
  • Positive Sentiment: Analyst targets remain above the current share price: Recent research includes bullish ratings and targets as high as $725. The broader analyst consensus remains “Moderate Buy,” with an average target of approximately $650, although ratings are not unanimous. Analysts Conflicted on United Therapeutics
  • Neutral Sentiment: CEO sold a relatively small portion of holdings: CEO Martine Rothblatt sold 9,500 shares for about $5.3 million, reducing her direct ownership by 2.84%. She still owns more than 324,000 shares, so the transaction may represent personal diversification rather than a change in business outlook. SEC Insider Trading Filing
  • Negative Sentiment: Tyvaso faces near-term pressure: RBC warned that United Therapeutics’ settlement with Liquidia could weigh on the outlook for Tyvaso, raising concerns about competition and growth for the company’s key pulmonary arterial hypertension franchise. United Therapeutics Tyvaso Outlook Faces Near-Term Pressure

Fundamentally, United Therapeutics’ previous quarter produced stronger-than-expected earnings per share, but revenue declined year over year and missed estimates. Investors will likely focus on Tyvaso sales, competitive developments and the effect of the buyback when the company reports third-quarter results on November 4.

Posted 1+ days agoAI Generated. May Contain Errors.

United Therapeutics Latest News

United Therapeutics (NASDAQ:UTHR) to Buy Back $2.00 billion in Stock
United Therapeutics Announces $2 Billion Share Buyback
SGIOY or UTHR: Which Is the Better Value Stock Right Now?

United Therapeutics Media Mentions By Week

United Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

UTHR
News Sentiment
▼
0.62

0.46
▲
Average
Healthcare
News Sentiment

United Therapeutics News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

UTHR Articles
This Week
▼
31

11
▲
UTHR Articles
Average Week

United Therapeutics Trends on MarketBeat

This week vs. last week
New Followers
2
+100%
Searches
3
+200%
Page Views
4,339
+13%
Get United Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for United Therapeutics dated 10/24/2026.
From Our Partners